Get to know our clinical trials
Phase 3 clinical trial to evaluate the efficacy and safety of maintenance therapy with sacituzumab tirumotecan versus standard therapy in platinum-sensitive recurrent ovarian cancer.
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF TIRUMOTECAN SACITUZUMAB IN MAINTENANCE TREATMENT WITH BEVACIZUMAB.
Technical Summary
- PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH SACITUZUMAB TIRUMOTECAN WITH OR WITHOUT BEVACIZUMAB VS. STANDARD THERAPY AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103).
- Code EudraCT: 2023-508015-23
- Protocol number: MK-2870-022
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: Sacituzumab tirumotecán
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.